by MM360 Staff | Jan 28, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Marisa Wexler, MS | Jan 27, 2026 | Myeloma News
A clinical trial in Australia that’s testing the genetic therapy KLN-1010 in people with hard-to-treat multiple myeloma has won regulatory approval to add new study sites in the U.S. The Phase 1 study, dubbed inMMyCAR (NCT07075185), will soon start enrolling patients...
by MM360 Staff | Jan 27, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Jan 27, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Marisa Wexler, MS | Jan 26, 2026 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted breakthrough designation to soficabtagene geleucel (sofi-cel), a cell therapy designed to treat relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (T-ALL/LBL), blood...
by MM360 Staff | Jan 24, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
